Targeting MET for glioma therapy

Ahmed J. Awad, Terence Burns, Ying Zhang, Roger Abounader

Research output: Contribution to journalArticle

32 Citations (Scopus)

Abstract

Glioblastoma multiforme is the most common and most lethal of all primary brain tumors. Even with the standard therapy, life expectancy is still poor, with an average survival of approximately 14 months following initial diagnosis. Hence, there is an urgent need for novel treatment strategies that inhibit proliferation and angiogenesis in high-grade gliomas. One such strategy consists of inhibiting receptor tyrosine kinases, including MET and/or its ligand hepatocyte growth factor (HGF). Because of their widespread involvement in human cancer, HGF and MET have emerged as promising therapeutic targets, and some inhibitory agents that target them have already entered clinical trials. In this paper, the authors highlight recent evidence implicating HGF/MET pathway deregulation in glioblastoma multiforme, discuss therapeutic approaches to inhibit HGF/MET signaling, and summarize ongoing clinical trials targeting this pathway.

Original languageEnglish (US)
Article numberE10
JournalNeurosurgical Focus
Volume37
Issue number6
DOIs
StatePublished - Jan 1 2014
Externally publishedYes

Fingerprint

Hepatocyte Growth Factor
Glioma
Glioblastoma
Clinical Trials
Proto-Oncogene Proteins c-met
Life Expectancy
Brain Neoplasms
Therapeutics
Ligands
Neoplasms

Keywords

  • Glioblastoma multiforme
  • Hepatocyte growth factor
  • MET

ASJC Scopus subject areas

  • Surgery
  • Clinical Neurology

Cite this

Targeting MET for glioma therapy. / Awad, Ahmed J.; Burns, Terence; Zhang, Ying; Abounader, Roger.

In: Neurosurgical Focus, Vol. 37, No. 6, E10, 01.01.2014.

Research output: Contribution to journalArticle

Awad, Ahmed J. ; Burns, Terence ; Zhang, Ying ; Abounader, Roger. / Targeting MET for glioma therapy. In: Neurosurgical Focus. 2014 ; Vol. 37, No. 6.
@article{eab53acf0f4147d88141730eb851aaad,
title = "Targeting MET for glioma therapy",
abstract = "Glioblastoma multiforme is the most common and most lethal of all primary brain tumors. Even with the standard therapy, life expectancy is still poor, with an average survival of approximately 14 months following initial diagnosis. Hence, there is an urgent need for novel treatment strategies that inhibit proliferation and angiogenesis in high-grade gliomas. One such strategy consists of inhibiting receptor tyrosine kinases, including MET and/or its ligand hepatocyte growth factor (HGF). Because of their widespread involvement in human cancer, HGF and MET have emerged as promising therapeutic targets, and some inhibitory agents that target them have already entered clinical trials. In this paper, the authors highlight recent evidence implicating HGF/MET pathway deregulation in glioblastoma multiforme, discuss therapeutic approaches to inhibit HGF/MET signaling, and summarize ongoing clinical trials targeting this pathway.",
keywords = "Glioblastoma multiforme, Hepatocyte growth factor, MET",
author = "Awad, {Ahmed J.} and Terence Burns and Ying Zhang and Roger Abounader",
year = "2014",
month = "1",
day = "1",
doi = "10.3171/2014.9.FOCUS14520",
language = "English (US)",
volume = "37",
journal = "Neurosurgical Focus",
issn = "1092-0684",
publisher = "American Association of Neurological Surgeons",
number = "6",

}

TY - JOUR

T1 - Targeting MET for glioma therapy

AU - Awad, Ahmed J.

AU - Burns, Terence

AU - Zhang, Ying

AU - Abounader, Roger

PY - 2014/1/1

Y1 - 2014/1/1

N2 - Glioblastoma multiforme is the most common and most lethal of all primary brain tumors. Even with the standard therapy, life expectancy is still poor, with an average survival of approximately 14 months following initial diagnosis. Hence, there is an urgent need for novel treatment strategies that inhibit proliferation and angiogenesis in high-grade gliomas. One such strategy consists of inhibiting receptor tyrosine kinases, including MET and/or its ligand hepatocyte growth factor (HGF). Because of their widespread involvement in human cancer, HGF and MET have emerged as promising therapeutic targets, and some inhibitory agents that target them have already entered clinical trials. In this paper, the authors highlight recent evidence implicating HGF/MET pathway deregulation in glioblastoma multiforme, discuss therapeutic approaches to inhibit HGF/MET signaling, and summarize ongoing clinical trials targeting this pathway.

AB - Glioblastoma multiforme is the most common and most lethal of all primary brain tumors. Even with the standard therapy, life expectancy is still poor, with an average survival of approximately 14 months following initial diagnosis. Hence, there is an urgent need for novel treatment strategies that inhibit proliferation and angiogenesis in high-grade gliomas. One such strategy consists of inhibiting receptor tyrosine kinases, including MET and/or its ligand hepatocyte growth factor (HGF). Because of their widespread involvement in human cancer, HGF and MET have emerged as promising therapeutic targets, and some inhibitory agents that target them have already entered clinical trials. In this paper, the authors highlight recent evidence implicating HGF/MET pathway deregulation in glioblastoma multiforme, discuss therapeutic approaches to inhibit HGF/MET signaling, and summarize ongoing clinical trials targeting this pathway.

KW - Glioblastoma multiforme

KW - Hepatocyte growth factor

KW - MET

UR - http://www.scopus.com/inward/record.url?scp=84916883583&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84916883583&partnerID=8YFLogxK

U2 - 10.3171/2014.9.FOCUS14520

DO - 10.3171/2014.9.FOCUS14520

M3 - Article

C2 - 25434379

AN - SCOPUS:84916883583

VL - 37

JO - Neurosurgical Focus

JF - Neurosurgical Focus

SN - 1092-0684

IS - 6

M1 - E10

ER -